Long-acting depot formulations of naltrexone for heroin dependence: a review
Effectiveness bank home page. Opens new windowReview abstract

This entry is for a review or synthesis of research findings added to the Effectiveness Bank but not fully analysed. Usually the entry consists only of the reference and an edited version of the original abstract, with either no commentary from Drug and Alcohol Findings or only essential points. The original review was not published by Findings; click Title to order a copy. Free reprints may be available from the authors – click prepared e-mail.

Links to other documents. Hover over for notes. Click to highlight passage referred to. Unfold extra text Unfold supplementary text
Copy title and link | Comment/query |

Long-acting depot formulations of naltrexone for heroin dependence: a review.

Krupitsky E.M., Blokhina E.A.
Current Opinion in Psychiatry: 2010, 23(3), p. 210–214.
Unable to obtain a copy by clicking title? Try asking the author for a reprint by adapting this prepared e-mail or by writing to Dr Krupitsky at kruenator@gmail.com. You could also try this alternative source.

Researcher responsible for a major Russian trial of long-acting naltrexone for the treatment of heroin dependence reviews the effectiveness and safety of this form of the drug and of another long-acting form implanted under the skin.

Summary Naltrexone is a perfect opioid antagonist [a drug which blocks the effects of opiate-type drugs] to treat heroin dependence: 50mg (one tablet) blocks the subjective effects of heroin for 24–36 hours, it is easy to administer (one tablet per day or two tablets every other day), it is well tolerated (has a relatively small number of side effects), and tolerance does not develop to the opioid antagonism. However, there is one problem that makes naltrexone relatively low in effectiveness in heroin dependence management: heroin addicts do not like it and they do not take it on the regular daily basis that is required. Long-acting, sustained-release formulations of naltrexone (implantable and injectable) might help to improve compliance and, thus, increase the efficacy of abstinence-oriented treatment of heroin dependence with naltrexone.

There have been several implantable and injectable formulations of naltrexone developed within the last decade. Some of them are effective and relatively well tolerated medications for relapse prevention in heroin addicts.

This review concludes that in general, long-acting, sustained-release naltrexone formulations (implantable and injectable) seem to be well tolerated and more effective than oral naltrexone and placebo for preventing relapse to heroin dependence. However, studies comparing an injectable formulation with oral naltrexone are needed. Also, studies comparing the safety and efficacy of different naltrexone implant technologies as well as comparing implantable and injectable formulations seem to be important.

Findings logo commentary This review was led by an author responsible for trials of oral and long-acting naltrexone in Russia. The article notes that he is a consultant to a pharmaceutical company which manufactures depot naltrexone. In the UK, neither implants nor depot injections of naltrexone have been licensed for medical use; they can still be and have been used, but patient and doctor have to accept the added responsibility of a product which has not yet been shown to meet the safety and efficacy requirements involved in licensing. These long-acting forms of naltrexone are a controversial technology. Readers are advised to refer to this Effectiveness Bank hot topic for more on the evidence and issues.

Last revised 27 July 2015. First uploaded 27 July 2015

Open Effectiveness Bank home page

Top 10 most closely related documents on this site. For more try a subject or free text search

STUDY 2010 Favorable mortality profile of naltrexone implants for opiate addiction

DOCUMENT 2012 An introduction to extended-release injectable naltrexone for the treatment of people with opioid dependence

REVIEW 2009 Pharmacotherapies for the treatment of opioid dependence: efficacy, cost-effectiveness and implementation guidelines

STUDY 2011 Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial

STUDY 2010 Naltrexone implants compared to methadone: outcomes six months after prison release

STUDY 2016 Extended-release naltrexone to prevent opioid relapse in criminal justice offenders

STUDY 2015 Opioid treatment at release from jail using extended-release naltrexone: a pilot proof-of-concept randomized effectiveness trial

STUDY 2009 Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone

STUDY 2006 Long-acting depot naltrexone extends opiate abstinence

STUDY 2003 Naltrexone implants could reduce the early relapse rate after detoxification